Ozurdex
Ozurdex is a pharmaceutical drug with 18 clinical trials. Historical success rate of 78.6%.
Success Metrics
Based on 11 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
3
Mid Stage
10
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
73.3%
11 of 15 finished
26.7%
4 ended early
0
trials recruiting
18
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification
One Year Trial Evaluating Safety of Ozurdex With Eylea
Compare the Efficacy of VItrectomy Combined With DExamethasone Implant Versus With Aflibercept in DME Patients Diagnosed by Intraoperative OCT (the VIDEO Study): Study Protocol for a Randomized Controlled Trial
Evaluation of OZURDEX® in Patients With Macular Edema Secondary to Retinal Vein Occlusion in China
Pro-permeability and Pro-fibrosis Factors in the Aqueous of Patients With Retinal Diseases
Clinical Trials (18)
Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification
One Year Trial Evaluating Safety of Ozurdex With Eylea
Compare the Efficacy of VItrectomy Combined With DExamethasone Implant Versus With Aflibercept in DME Patients Diagnosed by Intraoperative OCT (the VIDEO Study): Study Protocol for a Randomized Controlled Trial
Evaluation of OZURDEX® in Patients With Macular Edema Secondary to Retinal Vein Occlusion in China
Pro-permeability and Pro-fibrosis Factors in the Aqueous of Patients With Retinal Diseases
Combination OZURDEX® & EyLea® vs. OZURDEX® Monotherapy in IncompLete-Responders wIth Diabetic Macular Edema
Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma
Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema
Retrospective Trial on the Efficacy and Safety of Intravitreal Ozurdex in Patients With Diabetic Macular Edema.
Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study)
OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab
Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)
Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Treatment With Anti-VEGF Injections.
Multicentre Randomised Clinical Trial Comparing Fixed vs Pro re Nata (PRN) Dosing of 700 μg Dexamethasone
A Pilot Study of the Effectiveness of Intra-operative Ozurdex® in Vitrectomy Surgery for Epiretinal Membranes
Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion
Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema
Dexamethasone-Implant for the Treatment of Macula Edema Due to Irvine Gass Syndrome
All 18 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 18